Owkin is an AI Biotech company that leverages artificial intelligence to advance drug discovery and development, and to create diagnostic solutions for improved patient outcomes.

Owkin

MOSAIC research

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Mubadala Capital

Mubadala Capital Ventures

Bpifrance

Plug and Play

MACSF

Eight Roads Ventures

Google Ventures

Cathay Innovation

F-Prime Capital

Sanofi

Bristol-Myers Squibb

Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025.

Our cutting-edge AI engines will maximize its probability of success by identifying the optimal indication and patient sub-population and de-risk its ongoing clinical development.

Discover our Tx and Dx pipeline at owkin.com/pipeline

What are 5 ways digital pathology is transforming healthcare?

At the Digital Pathology Place webinar, we gained insights from Dr. Aleks 🔬 Żuraw, as she shared expertise on topics spanning from clinical practice to drug development.

Read our blog https://lnkd.in/dKvChGJG

Watch the webinar https://lnkd.in/dtYNxgsn

#ASCO24 has been a whirlwind of inspiration and innovation. But don't worry, the excitement isn't over yet. Watch our round-up video as we highlight the key takeaways from this world-leading conference.

🚀 Learn how we use #AI to unlock new insights from complex datasets to power precision medicine at https://lnkd.in/exAw9qze

🇫🇷 Tomorrow, our SVP of Data Science, Eric Durand, will be speaking at the first edition of mind Health Day on ‘AI and drug discovery: how is AI accelerating research today?’ along with Arnaud Bonnaffoux, Yann Gaston-Mathe, Philippe Moingeon, and Paul Rinaudo.

Register now: https://lnkd.in/gSU-fPHn

#ASCO24 Day 3: Meriem Sefta, Owkin’s Chief Diagnostics Officer, talks about the need for cost-effective and efficient diagnostic solutions to make precision medicine a reality. To tackle this challenge, we develop #AI #diagnostics for:

🔍 Clinical trial inclusion/exclusion criteria for better patient targeting
🎯 Increasing target population for existing drugs
💊 The selection of patient subgroups with novel biomarkers for novel drugs (CDx)

Visit us at booth #30095 or book a meeting with our team to learn more about how we work with pharma to develop innovative AI diagnostics https://lnkd.in/eCemTe_Q

Our Senior Research Scientist, Maria Telenczuk, will be speaking at the Google Developer Student Clubs | University of Amsterdam on ‘Federated Learning in Biotech’ on June 5 from 5:00 to 6:30 pm CET.

Maria will discuss what federated learning is and why it's so useful for deploying AI in the healthcare world.

Register now https://lnkd.in/eKGqgFre

COM:OWKIN

Owkin

Financials Not Available